Chimeric rhinoviruses

Details Chimeric rhinoviruses Chimeric rhinoviruses

1995-03-17

1998-02-03

Degen, Nancy

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

424 936, 4351723, C12N 701, A67K 3912

Patent

active

057143749

ABSTRACT:
Various novel recombinant chimeric human rhinoviruses are disclosed, including viruses comprising human rhinovirus 14 into which chimeric regions derived from influenza HA, poliovirus and HIV-1 have been incorporated. Chimeric human rhinoviruses are particularly advantageous as they are only mildly pathogenic, have numerous potential serotypes and can elicit significant mucosal and serum immunological response. Design considerations, methods, and examples are described. The chimeric rhinoviruses can be used as vaccines and for a variety of other immunotechnological applications including passive immunization, immunodiagnostic testing and antigenicity and immunogenicity studies.

REFERENCES:
patent: 5541100 (1996-07-01), Arnold et al.
Abraham and Colonno, "Many Rhinovirus Serotypes Share the Same Cellular Receptor", J. Virol., vol. 51 pp. 340-345, 1984.
Ada & Skehel, "Are peptides good antigens?" Nature, vol. 316, pp. 764-765, 1985.
Ahlers, J. D., et al., "Construction of an HIV-1 peptide vaccine containing a multideterminants helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations," J. Immunol., vol. 150 pp. 5647-5665, 1993.
Anderson, K.P. et al., "Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1," J. Infect. Dis., vol. 160, pp. 960-969, 1989.
Arnold et al., "The Use of Molecular-Replacement Phases for the Refinement of the Human Rhinovirus 14 Structure," J. Mol. Biol., vol. 210 pp. 91-111, 1989.
Arnold et al., "The Use of Molecular-Replacement Phases for the Refinement of the Human Rhinovirus 14 Structure", Acta Cryst., vol. A44 pp. 270-282, 1988.
Arnold et al., "Analysis of the Structure of a Common Cold Virus, Human Rhinovirus 14, Refined at a Resolution of 3.0A," J. Mol. Biol., vol. 211 pp. 763-801, 1990.
Barrett, N. et al., "Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity," AIDS Res. Hum. Retroviruses, vol. 5, pp. 159-171, 1989.
Belo, M. et al., "Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees," AIDS, vol. 5, pp. 169-176, 1991.
Belshe, R. B. et al., "Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection." J. Infec. Dis., vol. 168, pp. 1387-1395, 1993.
Berman, P. W., et al., "Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160," J. Virol., vol. 63, pp. 3489-3498, 1989.
Berman, P. W. et al., "Neutralization of multiple clinical isolates of HIV-1 by antisera raised against a monovalent subunit vaccine," Sixieme Colloque des Cent Gardes, pp. 293-297, 1991.
Berman, P. W. et al., "Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160," Nature, vol. 345, pp. 622-625, 1990.
Bittle, et al., "Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence," Nature, vol. 298, pp. 30-33, 1982.
Burke, et al., "A Cassette Vector for the Construction of Antigen Chimaeras of Poliovirus," J. Gen. Virol., vol. 70 pp. 2475-2479, 1989.
Callahan, et al., "Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14," Proc. Natl. Acad. Sci. U.S., vol. 82 pp. 732-736, 1985.
Conant and Hamparian, "Rhinoviruses: Basis for a Numbering System," J. Immunol., vol. 100, pp. 107-113, 1968.
Cooney, E. L. et al., "Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein," Proc. Natl. Acad. Sci. USA, vol. 90, pp. 1882-1886, 1993.
Dedieu, J.F. et al., "Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1," J. Virol., vol. 66, pp. 3161-3167, 1992.
Defoort, J. P., et al., "Macromolecular assemblage in the design of a synthetic AIDS vaccine," Pro. Natl. Acad. Sci. USA, vol. 89, pp. 3879-3883, 1992.
Delpeyroux, et al., "A Poliovirus Neutralization Epitope Expressed on Hybrid Hepatitis B Surface Antigen Particles," Science, vol. 233, pp. 472-475, 1986.
DiMarchi, et al., "Protection of Cattle Against Foot-and-Mouth Disease by a Synthetic Peptide," Science, vol. 232 pp. 639-641, 1986.
Dolin, R. et al., "The safety and immunogenicity of a human immunodeficiency virus type (HIV-1) recombinant gp160 candidate vaccine in humans," Ann. Intern. Med., vol. 114, pp. 119-127, 1991.
Englund, G., et al., "A Novel HIV-1 Isolate Containing Alterations Affecting the NF-.sub.k B Element," Virology, vol. 181 pp. 150-157, 1991.
Evans, DJ, et al., "An engineered poliovirus Chimaera elicits broadly reactive HIV-1 neutralizing antibodies," Nature, vol. 1339 pp. 3851-3881, 1989.
Frommhagen, "The Separation and Physicochemical Properties of the C and D Antigens of Coxsackievirus," J. Immunol., vol. 95, pp. 818-822, 1965.
Fultz, P. N. et al., "Vaccine protection of chimpanzees against challenge with HIV-1 infected peripheral blood mononuclear cells." Science, vol. 256, pp. 1687-1690, 1992.
Gallo, R.C., et al., "Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III)from Patients with AIDS and at Risk for AIDS," Science, vol. 224 pp. 500-503, 1984.
Ghiara, J., B., et al., "Crystal Structure of the Principal Neutralization Site of HIV-1," Science, vol. 264 pp. 82-85, 1994.
Girard, M. et al., "Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus." Proc.Natl. Acad. Sci. USA, vol. 88 pp. 542-546, 1991.
Gorny, M. K., et al., "Neutralization of Diverse Human Immunodeficiency Virus Type 1 Variants by an Anti-V3 Human Monoclonal Antibody," J. Virol., vol. 66 pp. 7538-7542, 1992.
Gorse, G. J. et al., "HIV-1 recombinant gp160 vaccine given in accelerated dose schedules," Clin. Exp. Immunol., vol. 98, pp. 178-184, 1994.
Gorse, G. J. et al., "Evaluation of HIV-1 MN V3 octameric peptide vaccine," Seventh Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, p. 94, 1994.
Goudsmit, J., et al., "Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees," Proc. Natl. Acad. Sci. USA, vol. 85 pp. 4478-4482, 1988.
Graham, B. S. et al., "Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults," J. Infect. Dis., vol. 167, pp. 533-537, 1993.
Griffiths, J.C., et al., "Induction of high-titer neutralizing antibodies using hybrid human immunodeficiencyvirus V3-Ty virus like particles in a clinically relevant adjuvant.," J. Virol., vol. 65, pp. 450-456, 1991.
Haffar, O.K., et al., "HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles.," Virology, vol. 183, pp. 487-495, 1991.
Kahn, J. O., et al., "Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1 .sub.sf2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers," J. Infect. Dis., vol. 170, pp. 1288-1291, 1994.
Kahn, J. O., et al., "A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects," AIDS Res. Hum. Retroviruses, vol. 8, pp. 1321-1325, 1992.
Keller, P. M. et al., "Identification of HIV vaccine candidate peptides by screening random phage epitope libraries," Virology, vol. 193, pp. 709-716, 1993.
Kohara, M. et al., "A Recombinant Virus between the Sabin 1 and Sabin 3 Vaccine Strains of Poliovirus as a Possible Candidate for a New Type 3 Poliovirus Live Vaccine Strain,"

Affiliated with

Also associated with

Rating

Chimeric rhinoviruses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric rhinoviruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric rhinoviruses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-661559